Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses - Wikidata - thesis-toulmin - TriplyDB

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

http://www.wikidata.org/entity/Q24658420

about

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer In vitro human cell line models to predict clinical response to anticancer drugs In vitro and in vivo models for analysis of resistance to anticancer molecular therapies PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy Activation of β-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes Systematic analysis of genotype-specific drug responses in cancer.CanProVar: a human cancer proteome variation database.PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001 Simple monitoring of gene targeting efficiency in human somatic cell lines using the PIGA gene.Cockayne syndrome group B protein regulates DNA double-strand break repair and checkpoint activation.Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.Personalizing health care: feasibility and future implications.Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells.Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.Absolute Quantification of Endogenous Ras Isoform Abundance HER2 missense mutations have distinct effects on oncogenic signaling and migration.The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.Oncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine.The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis.Challenges and opportunities for cell line secretomes in cancer proteomics.The development of high-content screening (HCS) technology and its importance to drug discovery.Improved methods of AAV-mediated gene targeting for human cell lines using ribosome-skipping 2A peptide.KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.Through a glass darkly: economics and personalised medicine.A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.

P2860

Q24600932-559D9DCA-0CEA-4451-93F3-7E212AACEF34 Q24604601-9B0A2CD4-5391-4815-A9B5-46FDC789D8F7 Q27000665-DF173F31-A52D-4E43-BEA4-21D7BBDEB191 Q27014174-B919EE51-F8F3-441E-BFE6-7A9E14665B67 Q27852473-B027A4E6-CA41-43FA-A126-B45B1FA130D9 Q27853338-86F68037-BFDC-40AF-B7C4-3D0DFEDD608D Q28285473-6758D050-D084-4605-8717-DEC1975AFDE5 Q28729157-F4EC65FD-7F51-42F5-9DA5-3051FA649203 Q28730141-C30FB066-E6BE-4938-A669-AC40BF71D387 Q33575305-49BC8B2B-3981-4B8E-9CF5-13FD14DE91BE Q33691397-63E035C0-A122-4D0A-8EF3-547779BEB91B Q34028766-84496C30-F564-4696-951E-7361A681FB58 Q34443086-B2160A29-D631-4886-B6E5-ECB5FBAFE7DB Q34469204-6891BBCB-3B42-4956-9FD7-E5E6A20E4D74 Q34592027-0A3A0359-D7CC-427B-A126-38C5A51F16D2 Q34616536-06E61ABD-FF8A-4365-B6F3-34CCDDDD0B79 Q34938911-480F8702-E53E-4666-A57A-6F9AB738D0EF Q35088938-1A00F3B1-95F8-4945-AC54-962680FFBA40 Q35751013-C23020A1-B9F3-43EC-B22C-ADC87AD8DC0F Q35839061-A7095525-3F83-4BBF-BB11-28FBCCA21128 Q36300320-CC295559-D7E8-4B1E-900B-48EDEE071AD5 Q36582552-C05812C1-DA70-4EE5-A48C-CDE9ACE99C84 Q36677712-7A183A3F-5183-425B-B57C-CDAB8DFC46C4 Q37215752-E7E5C44E-3DF6-47A2-BDD7-9DBBB3F47CFA Q37644761-F2CA9BAE-4FB9-452F-983A-6296A222BA30 Q37723730-1D74A10E-C60F-4FAB-A031-CE6A9AA17E64 Q37728190-D8BED8A1-9A12-42BC-A196-27E9553F3631 Q38270752-CFB92978-2B49-44FD-A565-AB0E812B0015 Q38772165-4AFAEAD8-7D88-46D5-AA94-D648D3C3B7BE Q38812436-0C2946C3-5B07-419B-B6D3-20E1A4381592 Q38854561-F38CB764-07FE-4438-8B78-5FE9F3F75EEE Q39053707-1841923D-E9E0-468C-8FDE-16DFE09A0648 Q39145520-D739C2A0-4986-466C-987B-3EC423546AD5 Q39180736-4FCCF160-FF1E-4380-B061-3606F876D2A5 Q39186065-01BBBD44-BC42-404C-B005-A2223E7B5EF0 Q39215523-DDACB444-18FA-4539-B776-241B421C3A56 Q39236770-43EFC7D5-002B-4355-BDC5-65E3993FF2D5 Q40026210-685AFE4B-DBB3-46C4-9F89-4027DA0A7AA9 Q41134871-149B3707-55E3-4A5B-8862-7117C1B14B13 Q41627000-A5210BB7-83F4-42E8-816E-06513BBC5C54

P2860

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

http://www.wikidata.org/entity/Q24658420

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Replacement of normal with mut ...... tation-specific drug responses

@ast

Replacement of normal with mut ...... tation-specific drug responses

@en

Replacement of normal with mut ...... tation-specific drug responses

@nl

type

label

Replacement of normal with mut ...... tation-specific drug responses

@ast

Replacement of normal with mut ...... tation-specific drug responses

@en

Replacement of normal with mut ...... tation-specific drug responses

@nl

prefLabel

Replacement of normal with mut ...... tation-specific drug responses

@ast

Replacement of normal with mut ...... tation-specific drug responses

@en

Replacement of normal with mut ...... tation-specific drug responses

@nl

P1433

Q24658420-78B86309-7FCB-4239-B267-E0026DDAD0ED

P1476

Q24658420-7DE71748-BEB5-4F43-AA11-D3868EBABE3A

P2093

Q24658420-052A42FB-1C41-474D-8B8D-22C4FFB6846D

Q24658420-10E2A4CC-D5FF-4476-AB09-0891C42FAD59

Q24658420-B98F26AE-215F-47E4-99F0-B941FAEA9509

Q24658420-C500A59D-48B5-4D68-A1F9-5AF60DECFAFA

Q24658420-C900D748-08DF-461D-BB78-4322F6BF4D3F

Q24658420-E12D008D-7C3E-49BC-9647-5691DE5513F8

Q24658420-E476E53B-D71F-4B7C-8AA7-26624AEE3863

P2860

Q24658420-04C88D8A-FCE4-4392-9E4D-1EE7049710F4

Q24658420-1B0120BF-62F5-4CFA-93D2-B26A4AF0DE04

Q24658420-258C0260-E602-4FF1-A73A-55E783C2C31F

Q24658420-371F0622-92F6-4F71-B2E4-8695BA0A175B

Q24658420-3CEE7850-3E80-4A0C-BA63-E899DA440DA6

Q24658420-3D5206CE-B6D4-41B9-87AE-9C7FFEA592EE

Q24658420-59AAC330-2062-45B4-B923-823303730542

Q24658420-69C6072C-9593-4147-BFD5-F9041D44EF59

Q24658420-6EBFBEA5-7E22-4696-B984-2869D0939F38

Q24658420-704EADED-1E1B-4F52-BB14-A297572C8154

P304

Q24658420-533C34E7-3B6B-4834-8B5F-5B6FB8C923EA

P31

Q24658420-5722B191-B441-4548-859A-9FA4935D0EBE

P356

Q24658420-AD9D4FE5-39D7-4076-B8BF-5010C5CDFD84

P407

Q24658420-B8E02606-E207-41F7-99EB-01D5C7AD9D7D

P433

Q24658420-C7B54065-4164-4E50-B4DF-C4BB21FEA1B3

P478

Q24658420-130C93CE-0045-40A9-82B6-815AF4F38D60

P50

Q24658420-2C143BA9-DD65-47D4-816B-BF6335B67D97

Q24658420-54C4BFE4-4EEE-4CBF-BF26-6B94289A35DE

Q24658420-658260BD-529A-4F83-9AC3-66A7688090CB

Q24658420-67AEA204-25AF-42E8-8CF2-04375EBBF0BD

Q24658420-A25FBEA1-642E-46D3-ABFE-1FB9183428E9

Q24658420-AD44DB1F-E42C-453C-A483-1A2172B4F714

Q24658420-D783858B-DA75-465A-9342-2081F79A1D31

Q24658420-E7B1A3BE-12E4-45DA-BAE0-158F95442535

P577

Q24658420-AC85DCEB-4C05-49D6-A230-0B3DB59C5EC6

P5875

Q24658420-F6901635-67E3-49F9-ACCE-B632B14AA5CB

P698

Q24658420-CB53D600-83C5-412B-BDAE-E9908CA54B46

P932

Q24658420-B6CB5D0C-DB64-4B73-95F7-2EB324F15ABE

P356

PNAS.0808757105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Replacement of normal with mut ...... tation-specific drug responses

@en

P2093

Carlotta Cancelliere

http://www.w3.org/2001/XMLSchema#string

Davide Zecchin

http://www.w3.org/2001/XMLSchema#string

Giulia Maria Stella

http://www.w3.org/2001/XMLSchema#string

Margherita Gallicchio

http://www.w3.org/2001/XMLSchema#string

Massimo Geuna

http://www.w3.org/2001/XMLSchema#string

Simona Emilia Flonta

http://www.w3.org/2001/XMLSchema#string

Simona Lamba

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Genetic targeting of the kinase activity of the Met receptor in cancer cells

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Mutations of the BRAF gene in human cancer

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Creation of human tumour cells with defined genetic elements

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures

Genistein, a specific inhibitor of tyrosine-specific protein kinases

FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data.

P304

20864-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0808757105

http://www.w3.org/2001/XMLSchema#string

P407

P433

52

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Federica Di Nicolantonio

Alberto Bardelli

Roberto Fantozzi

Mariangela Russo

Giovanni Appendino

P577

2008-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23687980

http://www.w3.org/2001/XMLSchema#string

P698

19106301

http://www.w3.org/2001/XMLSchema#string

P932

2634925

http://www.w3.org/2001/XMLSchema#string